February 13, 2021

Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): Preliminary Results of a Randomised, Controlled, Open-Label, Platform Trial

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

[pre-print; not peer-reviewed] Preliminary results from the RECOVERY trial, a randomized trial conducted among people hospitalized with COVID-19 in Britain, suggest that patients assigned to the interleukin (IL)-6 antibody tocilizumab group were more likely to be discharged from the hospital alive within 28 days than those receiving usual care (54% vs. 47%). Patients in the tocilizumab group were also less likely to require invasive mechanical ventilation or to die than those on usual care (33% vs. 38%).

Horby et al. (Jan 11, 2021). Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): Preliminary Results of a Randomised, Controlled, Open-Label, Platform Trial. Pre-print downloaded Feb 12 from https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1